VitaNova Life Sciences (VNOV) Liabilities and Shareholders Equity (2017 - 2026)

VitaNova Life Sciences (VNOV) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $2.4 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 8.43% year-over-year to $2.4 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $9.3 million (up 54.66% YoY) and the FY2026 annual result came in at $2.4 million, up 8.43% from the prior year.
• Liabilities and Shareholders Equity climbed to $2.4 million in Q2 2026, from $2.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.4 million in Q2 2026 to a low of $8728.0 in Q2 2023.
• A 5-year average of $1.1 million and a median of $1.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 73.97% — and 2024, when it soared 13567.03%.
• Tracing VNOV's Liabilities and Shareholders Equity over 5 years: stood at $35190.0 in 2022, then sank by 75.2% to $8728.0 in 2023, then soared by 14322.69% to $1.3 million in 2024, then surged by 85.59% to $2.3 million in 2025, then grew by 4.72% to $2.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.4 million (Q2 2026), $2.3 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.